SCHEMBL30042809

SCHEMBL30042809

O=C(N=NC(=S)Nc1cccc(C(F)(F)F)c1)c1cccc(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.64
▸ ALDH1A1 P00352 6/20 0.64
▸ MEN1 O00255 6/20 0.64
▸ KMT2A Q03164 6/20 0.64
▸ HTT P42858 3/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ CYP1A2 P05177 2/20 0.60
▸ CYP3A4 P08684 2/20 0.60
▸ CYP2D6 P10635 2/20 0.60
▸ CYP2C19 P33261 2/20 0.60
▸ RXFP1 Q9HBX9 1/20 0.55
▸ NPSR1 Q6W5P4 3/20 0.50
▸ GAA P10253 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ SLC2A1 P11166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053989 0.79 ALDH1A1 (0.80) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL30387868 0.76 MAPT (1.00) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL24169274 0.76 MAPT (1.00) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL14459434 0.76 KMT2A (0.74) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL23539712 0.74 MAPT (0.70) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL9939658 0.73 KMT2A (0.50) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL9924130 0.72 DCUN1D1 (0.52) MAPTALDH1A1MEN1KMT2AHTT
Chlorobenzene SCHEMBL27823042 0.72 MAPT (0.68) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL15531106 0.71 RXFP1 (1.00) RXFP1
SCHEMBL23336404 0.71 P2RX1 (0.76) MAPTALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279741-A 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders 医肯纳肿瘤学公司 2022-11-01 — — CN disclosed
Send feedback